Reni Benjamin
Stock Analyst at JMP Securities
(1.47)
# 3,348
Out of 4,884 analysts
194
Total ratings
39.75%
Success rate
-12.78%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
BPMC Blueprint Medicines | Downgrades: Market Perform | n/a | $128.35 | - | 22 | Jun 3, 2025 | |
INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $16.33 | - | 10 | May 15, 2025 | |
BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $7.43 | +196.10% | 14 | May 2, 2025 | |
CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.70 | +187.69% | 5 | Apr 2, 2025 | |
BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.38 | +165.89% | 9 | Mar 31, 2025 | |
ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.19 | +320.17% | 7 | Mar 14, 2025 | |
INCY Incyte | Reiterates: Market Perform | n/a | $68.45 | - | 28 | Mar 11, 2025 | |
ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.61 | - | 5 | Mar 7, 2025 | |
HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.07 | +273.83% | 5 | Jan 14, 2025 | |
CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.76 | +127.27% | 1 | Aug 8, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $2.28 | - | 4 | Nov 12, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.07 | - | 2 | Dec 3, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.36 | - | 3 | Jun 14, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.25 | +6,300.00% | 1 | Oct 22, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $18.28 | -45.30% | 2 | Oct 12, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.19 | +56.74% | 6 | Jun 24, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $5.86 | +377.82% | 11 | Jun 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $27.50 | - | 2 | Jun 2, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $24.55 | +62.93% | 4 | Jun 2, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.32 | - | 7 | May 15, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.75 | - | 11 | May 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.79 | +403.84% | 5 | Apr 29, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.76 | - | 10 | Mar 14, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $8.23 | -2.79% | 1 | Mar 12, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $56.01 | +7.12% | 1 | Mar 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.62 | - | 1 | Feb 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $241.76 | +30.29% | 1 | Feb 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $93.63 | - | 1 | Feb 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $237.55 | +11.56% | 1 | Feb 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.20 | +431.25% | 3 | Nov 10, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.29 | - | 3 | Nov 15, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.74 | - | 4 | Jun 14, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.46 | - | 2 | Feb 7, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $36.72 | -67.32% | 1 | Sep 25, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.58 | - | 1 | Nov 15, 2017 |
Blueprint Medicines
Jun 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $128.35
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $16.33
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $7.43
Upside: +196.10%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.70
Upside: +187.69%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.38
Upside: +165.89%
Allogene Therapeutics
Mar 14, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.19
Upside: +320.17%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $68.45
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.61
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.07
Upside: +273.83%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.76
Upside: +127.27%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $2.28
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.07
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $7.36
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.25
Upside: +6,300.00%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $18.28
Upside: -45.30%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.19
Upside: +56.74%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $5.86
Upside: +377.82%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $27.50
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $24.55
Upside: +62.93%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.32
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.75
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.79
Upside: +403.84%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.76
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $8.23
Upside: -2.79%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $56.01
Upside: +7.12%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.62
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $241.76
Upside: +30.29%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $93.63
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $237.55
Upside: +11.56%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.20
Upside: +431.25%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.29
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.74
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.46
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $36.72
Upside: -67.32%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $13.58
Upside: -